Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 in BRAF V600E-mutant metastatic colorectal cancer
CTR20212777Phase 2Completed
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208 in metastatic colon cancer (mCRC), sponsored by Suzhou Runxin Biotechnology. Started Nov 2021; status: completed.
02
Drugs
HLX208
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20212777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212777.